Anavex
New York
About Anavex
Anavex Life Sciences Corp. is a biopharmaceutical company engaged in the discovery and development of new drugs for the treatment of neurological diseases and cancer, utilizing its proprietary drug discovery SIGMACEPTOR™ platform. The Anavex portfolio comprises novel, wholly owned sigma receptor agonists and antagonists. The company’s lead drug candidate for Alzheimer’s Disease (AD), ANAVEX 2-73, has successfully completed a Phase 1 single ascending dose (SAD) clinical trial. The company has also started scale-up manufacturing for ANAVEX 1-41, its second lead compound, targeting depression and AD. With sufficient quantities of ANAVEX 1-41 in hand, the company will be in a position to advance the program and begin preclinical studies on large animals in the near term.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $212.6M
- Funding stage: IPO
- Last round: Post-IPO Equity (Aug 2025)
- Ticker: nasdaq:AVXL
- Website: anavex.com
- Phone: 14164890092
Industries & Categories
Biopharma, Biotechnology, Health Care, Manufacturing, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/anavex-39910 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.